Profound symptomatic hypogammaglobulinemia: A rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.

Autoimmunity Reviews

Volumn 13, Issue 10, 2014, Pages 1055-1063

  Levy, Romain ^a   Mahévas, Matthieu ^a   Galicier, Lionel ^b   Boutboul, David ^b   Moroch, Julien ^a   Loustau, Valentine ^a   Guillaud, Constance ^a   Languille, Laeticia ^a   Fain, Olivier ^c   Bierling, Philippe ^a   Khellaf, Medhi ^a   Michel, Marc ^a   Oksenhendler, Eric ^b   Godeau, Bertrand ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISONE;

B LYMPHOCYTE; DISEASE SEVERITY; DRUG INFUSION; FRANCE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INCIDENCE; RECURRENT INFECTION; REVIEW; SYSTEMATIC REVIEW (TOPIC); ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; FEMALE; IMMUNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; FRANCE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 84908148767     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.036     Document Type: Review

References (64)

1. Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
2. Auger S., Duny Y., Rossi J.F., Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 2012, 158:386-398.
3. Khellaf M. Safety and efficacy of rituximab in adult's immune thrombocytopenia (ITP): results of follow-up in 252 patients from the prospective French ITP-Ritux registry. ASH Congr. Blood November 15 2013, 122(21). [Abstract 450].
4. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
5. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98:952-957.
6. Stasi R., Stipa E., Forte V., Meo P., Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002, 99:3872-3873.
7. Giagounidis A.A.N., Anhuf J., Schneider P., Germing U., Söhngen D., Quabeck K., et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002, 69:95-100.
8. Narang M., Penner J.A., Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol 2003, 74:263-267.
9. Zaja F., Vianelli N., Sperotto A., De Vita S., Iacona I., Zaccaria A., et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003, 88:538-546.
10. Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M.A., Leonard J.P., Amadori S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004, 125:232-239.
11. Braendstrup P., Bjerrum O.W., Nielsen O.J., Jensen B.A., Clausen N.T., Hansen P.B., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005, 78:275-280.
12. Garcia-Chavez J., Majluf-Cruz A., Montiel-Cervantes L., Esparza M.G.-R., Vela-Ojeda J. Mexican hematology study group. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 2007, 86:871-877.
13. Schweizer C., Reu F.J., Ho A.D., Hensel M. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Ann Hematol 2007, 86:711-717.
14. Medeot M., Zaja F., Vianelli N., Battista M., Baccarani M., Patriarca F., et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol 2008, 81:165-169.
15. Godeau B., Porcher R., Fain O., Lefrère F., Fenaux P., Cheze S., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008, 112:999-1004.
16. Alasfoor K., Alrasheed M., Alsayegh F., Mousa S.A. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol 2009, 88:239-243.
17. Ling H.T., Field J.J., Blinder M.A. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 2009, 84:418-421.
18. Hasan A., Michel M., Patel V., Stasi R., Cunningham-Rundles S., Leonard J.P., et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol 2009, 84:661-665.
19. Pasa S., Altintas A., Cil T., Danis R., Ayyildiz O. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. J Thromb Thrombolysis 2009, 27:329-333.
20. Zaja F., Baccarani M., Mazza P., Bocchia M., Gugliotta L., Zaccaria A., et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115:2755-2762.
21. Zaja F., Vianelli N., Volpetti S., Battista M.L., Defina M., Palmieri S., et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010, 85:329-334.
22. De la Rubia J., Moscardó F., Gómez M.J., Guardia R., Rodríguez P., Sebrango A., et al. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci 2010, 43:299-303.
23. Li Z., Mou W., Lu G., Cao J., He X., Pan X., et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol 2011, 93:91-98.
24. Patel V.L., Mahévas M., Lee S.Y., Stasi R., Cunningham-Rundles S., Godeau B., et al. Outcomes 5years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012, 119:5989-5995.
25. Arnold D.M., Heddle N.M., Carruthers J., Cook D.J., Crowther M.A., Meyer R.M., et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 2012, 119:1356-1362.
26. Červinek L., Černá O., Čaniga M., Konířová E., Hluší A., Šimkovič M., et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. Int J Hematol 2012, 96:594-599.
27. Mahévas M., Ebbo M., Audia S., Bonnotte B., Schleinitz N., Durand J.-M., et al. Efficacy and safety of rituximab given at 1,000mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol 2013, 88:858-861.
28. Gudbrandsdottir S., Birgens H.S., Frederiksen H., Jensen B.A., Jensen M.K., Kjeldsen L., et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013, 121:1976-1981.
29. Gómez-Almaguer D., Tarín-Arzaga L., Moreno-Jaime B., Jaime-Pérez J.C., Ceballos-López A.A., Ruiz-Argüelles G.J., et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol 2013, 90:494-500.
30. Bussel J.B., Lee C.S., Seery C., Imahiyerobo A.A., Thompson M.V., Catellier D., et al. Rituximab and 3 dexamethasone cycles provide responses similar to splenectomy in women and those with Immune Thrombocytopenia less than 2years duration. Haematologica Jul 2014, 99(7):1264-1271.
31. Wang J., Wiley J.M., Luddy R., Greenberg J., Feuerstein M.A., Bussel J.B. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005, 146:217-221.
32. Bennett C.M., Rogers Z.R., Kinnamon D.D., Bussel J.B., Mahoney D.H., Abshire T.C., et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006, 107:2639-2642.
33. Parodi E., Rivetti E., Amendola G., Bisogno G., Calabrese R., Farruggia P., et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol 2009, 144:552-558.
34. Peñalver F.J., Jiménez-Yuste V., Almagro M., Alvarez-Larrán A., Rodríguez L., Casado M., et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006, 85:400-406.
35. Zaja F., Battista M.L., Pirrotta M.T., Palmieri S., Montagna M., Vianelli N., et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008, 93:930-933.
36. Zaja F., Volpetti S., Chiozzotto M., Puglisi S., Isola M., Buttignol S., et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol 2012, 87:886-889.
37. Parodi E., Nobili B., Perrotta S., Rosaria Matarese S.M., Russo G., Licciardello M., et al. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol 2006, 84:48-53.
38. Quartier P., Tournilhac O., Archimbaud C., Lazaro L., Chaleteix C., Millet P., et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 2003, 36:e47-e49.
39. Adeli M.M.G., Eichner B.H., Thornburg C., Williams L. Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. Pediatr Hematol Oncol 2009, 26:566-572.
40. Cooper N., Davies E.G., Thrasher A.J. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 2009, 146:120-122.
41. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
42. Provan D., Stasi R., Newland A.C., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
43. Cooper N., Arnold D.M. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010, 149:3-13.
44. Isenberg D.A. Rituximab-it was the best of times, it was the worst of times. Autoimmun Rev 2012, 11:790-791.
45. Kattah A.G., Fervenza F.C., Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev 2013, 12:854-859.
46. Saadoun D., Bodaghi B., Bienvenu B., Wechsler B., Sene D., Trad S., et al. Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev 2013, 12:774-783.
47. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J., Danowski A., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014, 13:685-696.
48. Van Vollenhoven R.F. Rituximab - shadow, illusion or light?. Autoimmun Rev 2012, 11:563-567.
49. Gómez-Puerta J.A., Quintana L.F., Stone J.H., Ramos-Casals M., Bosch X. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev 2012, 11:646-652.
50. Terrier B., Marie I., Launay D., Lacraz A., Belenotti P., de Saint-Martin L., et al. Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey. Autoimmun Rev 2014, 13:630-634.
51. Díaz-Lagares C., Croca S., Sangle S., Vital E.M., Catapano F., Martínez-Berriotxoa A., et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012, 11:357-364.
52. Khattri S., Zandman-Goddard G., Peeva E. B-cell directed therapies in antiphospholipid antibody syndrome-new directions based on murine and human data. Autoimmun Rev 2012, 11:717-722.
53. Berman H., Rodríguez-Pintó I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013, 12:1085-1090.
54. Edwards J.C.W., Cambridge G., Leandro M.J. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006, 20:915-928.
55. Van Vollenhoven R.F., Emery P., Bingham C.O., Keystone E.C., Fleischmann R.M., Furst D.E., et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013, 72:1496-1502.
56. Sneller M.C., Strober W., Eisenstein E., Jaffe J.S., Cunningham-Rundles C. NIH conference. New insights into common variable immunodeficiency. Ann Intern Med 1993, 118:720-730.
57. Cunningham-Rundles C., Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol (Orlando Fla) 1999, 92:34-48.
58. Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 2002, 16:61-64.
59. Oksenhendler E., Gérard L., Fieschi C., Malphettes M., Mouillot G., Jaussaud R., et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008, 46:1547-1554.
60. Wehr C., Kivioja T., Schmitt C., Ferry B., Witte T., Eren E., et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008, 111:77-85.
61. Chapel H., Lucas M., Lee M., Bjorkander J., Webster D., Grimbacher B., et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008, 112:277-286.
62. Michel M., Chanet V., Galicier L., Ruivard M., Levy Y., Hermine O., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004, 83:254-263.
63. Ochtrop M.L.G., Goldacker S., May A.M., Rizzi M., Draeger R., Hauschke D., et al. T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. Blood 2011, 118:309-318.
64. Gobert D., Bussel J.B., Cunningham-Rundles C., Galicier L., Dechartres A., Berezne A., et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 2011, 155:498-508.